Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OTIC

Otonomy (OTIC) Stock Price, News & Analysis

Otonomy logo

About Otonomy Stock (NASDAQ:OTIC)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.0085
$0.0085
50-Day Range
$0.01
$0.12
52-Week Range
$0.01
$2.54
Volume
N/A
Average Volume
937,525 shs
Market Capitalization
$582,479.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Remove Ads
Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Stock News Headlines

Otonomy, Inc.: Otonomy Provides Corporate Update
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Otonomy Provides Corporate Update
5 Investors Betting Big on Otonomy (OTIC) Stock
Why Is Otonomy (OTIC) Stock Up 97% Today?
See More Headlines

OTIC Stock Analysis - Frequently Asked Questions

Otonomy, Inc. (NASDAQ:OTIC) released its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.19).

Based on aggregate information from My MarketBeat watchlists, some other companies that Otonomy investors own include Trevena (TRVN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Fortress Biotech (FBIO) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/10/2021
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-51,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$130,000.00
Price / Cash Flow
N/A
Book Value
$0.97 per share
Price / Book
0.01

Miscellaneous

Free Float
67,780,000
Market Cap
$582,479.50
Optionable
Optionable
Beta
1.54

Social Links

10 Stocks Set to Soar in Spring 2025 Cover

Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.

Get This Free Report

This page (NASDAQ:OTIC) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners